Danwang Medical is a biopharma and biotechnology startup founded in 2019 with the slogan "Empowering medical advancements through regenerative medicine and organoid technology for precise diagnostics and innovative therapies." The company specializes in advanced clinical transformation technology services in regenerative medicine for disease diagnosis and treatment. This encompasses organoid drug sensitivity testing, organoid disease models, organoid drug development, and organoid chips. The CNY120.00M Series A investment received on 14 October 2021 from Delian Capital, Kunlun Capital, Guofang Capital reflects the attractiveness of their innovative approach. Danwang Medical aims to utilize the latest clinical transformation technology in regenerative medicine to provide personalized treatment technology that is precise, efficient, and of high quality for new drug research and development enterprises. This startup's focus on utilizing cutting-edge technology to enhance medical treatments positions it as a potentially promising venture for investors in the biopharma and biotechnology industries.
Danwang Medical
Empowering medical advancements through regenerative medicine and organoid technology for precise diagnostics and innovative therapies.
General Information
BounceWatch is an independent company data service, not affiliated with Danwang Medical. To contact Danwang Medical, visit d1med.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Danwang Medical compare?
A PDF of Danwang Medical and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Danwang Medical soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Danwang Medical on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
About Danwang Medical
Business keywords: Regenerative Medicine, Organoid Technology, Clinical Transformation, Disease Diagnosis, Treatment, Drug Sensitivity Testing, New Drug Screening, Tumor Marker Development, Precision Medicine, Therapeutic Innovations
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | CNY120.00M | 3 |
|
14 Oct 2021 |
| Angel Round | Undisclosed | - |
|
01 Feb 2021 |
Danwang Medical Alternatives & Competitors
View All Alternatives
Commercialization of the world's first organoid treatment
Development of innovative treatments for cancer & intractable diseases through the RNA-based platfor...
Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel,...
FAQ About Danwang Medical
Source: BounceWatch company record for Danwang Medical, https://bouncewatch.com/company/danwang-medical, updated 26 December 2024. When citing, please name BounceWatch and link this page.
